# US 11,077,095 B2 · Methods for treating neurodegenerative disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,077,095 B2
- Document ID: US11077095B2
- Status: Granted
- Kind: B2
- Application number: 16/488,327
- Filed: 2018-02-23
- Published: 2019-12-12
- Granted: 2021-08-03
- Earliest claimed: 2017-02-24
- Assignees: Alzheon, Inc.
- Applicants: Alzheon, Inc.
- Inventors: Petr Kocis; Martin Tolar; John Hey
- Web page: https://patentgrep.com/patent/US11077095B2

## CPC

- A61K 31/185: Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327)
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/381: having five-membered rings
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/415: 1,2-Diazoles
- A61K 31/4152: having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
- A61K 31/4168: having a nitrogen attached in position 2, e.g. clonidine
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/42: Oxazoles
- A61K 31/423: condensed with carbocyclic rings
- A61K 31/426: 1,3-Thiazoles
- A61K 31/428: condensed with carbocyclic rings
- A61K 31/433: Thidiazoles
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4425: Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/52: Purines, e.g. adenine
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 31/536: ortho- or peri-condensed with carbocyclic ring systems
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of treating a disease characterized by amyloid aggregates are provided herein.

## Claims

### Claim 1

A method of treating Alzheimer's disease comprising the step of administering to a subject in need thereof a compound selected from:
or a pharmaceutically acceptable salt of any of the foregoing.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is selected from:
or a pharmaceutically acceptable salt of any of the foregoing.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound is formulated into a pharmaceutically acceptable composition additionally comprising a pharmaceutically acceptable carrier.

### Claim 4 (depends on 2)

The method of claim 2, wherein the compound is formulated into a pharmaceutically acceptable composition additionally comprising a pharmaceutically acceptable carrier.